Point of Care Diagnostic Testing World Markets

1. Overview: 1.1 About this Report; 1.2 Scope of the Report; 1.3 Objectives; 1.4 Methodology; 1.5 Executive Summary
2. Overview of Diagnostic Testing Point of Care: 2.1 POCT Testing Sites; 2.2 POCT Market Structure; 2.3 New Directions in Clinical IVD Testing
3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth, Share and Competitors: 3.1 Global POCT Market; 3.2 U.S. POCT Market; 3.3 European POCT Market

3.3.1 German POCT Diagnostic Market

3.3.2 U.K. POCT Diagnostic Market

3.3.2.1 U.K. POCT Market Statistics

3.3.2.2 U.K. Competitive Analysis

3.3.2.3 U.K. Market Access

3.3.3 French POCT Diagnostic Market

3.3.4 Italian POCT Diagnostic Market

3.3.5 Spanish POCT Diagnostic Market

3.3.6 Scandinavian POCT Diagnostic Market

3.3.7 Swedish POCT Diagnostic Market

3.3.8 Finland POCT Diagnostic Market

3.3.9 Norway POCT Diagnostic Market

3.3.10 Swiss POCT Diagnostic Market

3.3.11 Dutch POCT Diagnostic Market

3.3.12 Belgian POCT Diagnostic Market

3.3.13 Portugal POCT Diagnostic Market

3.3.14 Austria POCT Diagnostic Market

3.3.15 Greek POCT Diagnostic Market

3.3.16 Poland POCT Diagnostic Market

3.3.17 Czech Republic POCT Diagnostic Market

3.3.18 Turkish POCT Diagnostic Market; 3.4 Asian POCT Markets

3.4.1 Japanese POCT Diagnostic Market

3.4.2 Indian POCT Diagnostic Market

3.4.3 Chinese POCT Diagnostic Market; 3.5 Rest of the World POCT Market

3.5.1 Canada POCT Diagnostic Market

3.5.2 Brazil POCT Diagnostic Market

3.5.3 Australia POCT Diagnostic Market; 3.6 Overview of Asian Healthcare Market

3.6.1 Singapore

3.6.2 Malaysia

3.6.3 Thailand

3.6.4 Indonesia

3.6.5 Philippines

3.6.6 South Korea

3.6.7 Taiwan
4. POCT Individual Markets: 4.1 Glucose Testing; 4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors

4.2.1 World Market

4.2.2 U.S. Market

4.2.3 European Market

4.2.3 Alternate Glucose Monitoring Products

4.2.4 HbA1c POCT; 4.3 Blood Gas and Electrolytes

4.3.1 Whole Blood Lactate; 4.4 Rapid Coagulation Tests

4.4.1 World POCT Coagulation Market

4.4.2 U.S. Coagulation Market

4.4.2 European Coagulation Market; 4.5 Rapid Cardiac Markers

4.5.1 U.S. Market

4.5.2 European Market; 4.6 Drugs of Abuse Screening Testing

4.6.1 Acetaminophen

4.6.2 Tricyclic Antidepressants (TCAs)

4.6.3 Other Toxic Drugs

4.6.4 Drug Testing Selectivity

4.6.5 Methaqualone and Phencyclidine (PCP)

4.6.6 Tetrahydrocannabinol

4.6.7 Drug Panels by Toxidromes

4.6.8 Alcohol Testing; 4.7 Urine Strips; 4.8 Pregnancy Tests; 4.9 Fecal Occult Blood; 4.10 Hemoglobin Testing; 4.11 Miscellaneous Rapid Tests

4.11.1 Estriol

4.11.2 Fetal Fibronectin (fFN)

4.11.3 H. pylori

4.11.4 Vaginal pH and Vaginitis

4.11.5 Bladder Cancer

4.11.6 Fetal Status; 4.12 Human Immunodeficiency Virus (HIV); 4.13 Cholesterol; 4.14 Infectious Disease

4.14.1 C. difficile

4.14.2 Giardia

4.14.3 Salmonella and Campylobacter

4.14.4 Malaria Testing

4.14.5 Influenza Testing

4.14.6 Strep Testing

4.14.7 Chlamydia

4.14.8 Mononucleosis

4.14.9 Rubella

4.14.10 Methicillin-Resistant Staphylococcus aureus (MRSA)

4.14.11 Hepatitis

4.14.12 Gonorrhea

4.14.13 Tuberculosis (TB)

4.14.14 Herpes Simplex Virus Type-2; 4.15 Infant Jaundice; 4.16 Anthrax; 4.15 Rupture of Fetal Membranes (ROM); 4.16 Food Pathogens; 4.17 Typhoid
5. POCT: Reagents and Equipment: 5.1 Blood Glucose Monitoring

5.1.1 LifeScan

5.1.2 Roche Accu-Chek

5.1.3 Siemens Healthcare Diagnostics

5.1.4 Cholestech (Acquired by Inverness Medical Innovations)

5.1.5 Abbott Diabetes Care

5.1.6 International Technidyne Corporation

5.1.7 HemoCue

5.1.8 Stanbio/GDS Technology

5.1.9 Disetronic Medical Systems

5.1.10 Medtronic MiniMed

5.1.11 Abaxis; 5.2 Blood Gas and Electrolytes

5.2.1 V�samed, Inc. (f/k/a Optical Sensors, Inc.)

5.2.2 Roche Corporation

5.2.3 TechnoMedica

5.2.4 Siemens Healthcare Diagnostics

5.2.5 Instrumentation Laboratory

5.2.6 Nova Biomedical

5.2.7 Radiometer

5.2.8 Abbott Laboratories

5.2.9 Span Diagnostics

5.2.10 Avox Systems

5.2.11 ITC

5.2.12 OPTImedical; 5.3 Rapid Coagulation Tests

5.3.1 POC Coagulation Instrument Description

5.3.1.1 Roche Diagnostics Corp.

5.3.1.2 Abbott Laboratories

5.3.1.3 International Technidyne Corp.

5.3.1.4 Medtronic

5.3.1.5 HemoSense

5.3.1.6 Helena Laboratories Point of Care

5.3.1.7 Sienco, Inc.

5.3.1.8 Accumetrics

5.3.2 Connectivity Issues

5.3.3 Cost Benefits

5.3.4 Quality Control Issues

5.3.5 Certification for POC Coagulation Devices; 5.4 Rapid Cardiac Markers

5.4.1 Nanogen

5.4.2 Biosite Diagnostics

5.4.3 Roche Diagnostics

5.4.4 Ani Biotech

5.4.5 Response Biomedical Corporation

5.4.6 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics,Diagnostic Products Corporation, and Dade Behring)

5.4.7 Lab21 Limited

5.4.8 Abbott Laboratories

5.4.9 LifeSign (Princeton BioMediTech Corp)

5.4.10 Mitsubishi Kagaku Iatron; 5.5 Rapid Drugs of Abuse

5.5.1 Biosite Diagnostics (now a brand of Inverness Medical Innovations)

5.5.2 Abbott Diagnostics

5.5.3 Roche Diagnostics

5.5.4 BioScan Screening Systems, Inc.

5.5.5 American Bio Medica Corp.

5.5.6 Phamatech, Inc.

5.5.7 Worldwide Medical

5.5.8 OraSure

5.5.9 LifePoint

5.5.10 Avitar, Inc.

5.5.11 Cozart Biosciences

5.5.12 Pathtech

5.5.13 Alfa Scientific Designs, Inc.

5.514 TCPI, Inc.

5.5.15 Roche

5.5.16 Siemens Corporation

5.5.17 Diagnostic Chemical, Ltd.

5.5.18 Quidel

5.5.19 HemoCue (Quest); 5.7 Rapid Pregnancy and Fertility Tests; 5.8 Fecal Occult Blood

5.8.1 Helena Laboratories

5.8.2 Biomerica

5.8.3 Beckman Coulter

5.8.4 Worldwide Medical

5.8.5 Aerscher Diagnostics

5.8.6 Enterix

5.8.7 Medix Biochemica

5.9 Hemoglobin Testing

5.9.1 Wampole Laboratories

5.9.2 HemoCue, Inc.

5.9.3 Stanbio/GDS Technology; 5.10 Miscellaneous Rapid Tests

5.10.1 Triage C. difficile Panel

5.10.2 Ketoacids

5.10.3 Acetaminophen

5.10.4 Estriol

5.10.5 H. pylori

5.10.6 Vaginal Fluid pH and Vaginitis

5.10.7 Prostate Specific Antigen (PSA)

5.10.8 Bladder Cancer

5.10.9 Other Rapid Cancer Tests

5.10.10 Fetal Status (PROM)

5.10.11 Osteoporosis; 5.11 HIV; 5.12 Cholesterol

5.12.1 Cholestech (now a brand of Inverness Medical Innovations)

5.12.2 Actimed Laboratories

5.12.3 StatSite Meter

5.12.4 Polymer Technology Systems

5.12.5 PreMD Inc. (f/k/a International Medical Innovations Inc. (IMI))

5.12.6 Abaxis, Inc.; 5.13 Infectious Disease

5.13.1 C. difficile

5.13.2 Giardia

5.13.3 Dengue Fever

5.13.4 Malaria Testing

5.13.5 Rapid Influenza Testing

5.13.6 Streptococcus Testing

5.13.7 Chlamydia

5.13.8 Mononucleosis

5.13.9 Rubella

5.13.10 Staphylococcus aureus and MRSA

5.13.11 Hepatitis

5.13.12 E. coli O157

5.13.13 Gonorrhea Testing

5.13.14 Smallpox

5.13.15 SARS

5.13.16 Rabies

5.13.17 Tuberculosis

5.13.18 Avian Flu

5.13.19 West Nile Virus

5.13.20 Herpes Simplex Virus Type-2; 5.14 Infant Jaundice; 5.15 Anthrax; 5.16 Homeland Defense; 5.17 BSE (Mad Cow Disease); 5.18 Tuberculosis; 5.19 Typhoid; 5.20 Avian flu; 5.21 Food Pathogens (Salmonella, Listeria, Campylobacter); 5.22 Ruptured Fetal Membranes (ROM)
6. POCT: Growth Regulators: 6.1 Moderators of Growth; 6.2 Personnel Acceptance; 6.3 Key People for POCT; 6.4 Information Management Issues

6.4.1 Elements of Information Management for POCT: Information Processing Capabilities

6.4.2 Data Mining

6.4.3 Middleware

6.4.4 Web Portals

6.4.5 POCT-1A Standard; 6.5 Key Elements for POCT; 6.6 POCT and Reimbursement; 6.7 Effectiveness of Clinical Outcomes; 6.8 Rapid Near-Patient Testing in Hospitals; 6.9 Satellite Facilities; 6.10 Regionalization of Laboratory Care; 6.11 Requirements for POCT; 6.12 Locations of Point of Care for Patient Care; 6.13 Benefits of POCT; 6.14 Cost Elements of POCT; 6.15 Necessary Functions in POCT; 6.16 TAT for POCT; 6.17 Clinical Laboratory Improvement Amendments (CLIA); 6.18 Sexually-Transmitted Diseases in Underdeveloped Countries
7. Business Trends in the Point of Care Sector: 7.1 Sector Consolidation; 7.2 Diagnostic Testing Growth Trends; 7.3 Acquisition, License Agreements, Internal Development and Partnerships; 7.4 Product Testing Depth in POCT; 7.5 Government Regulation

7.5.1 U.S. Regulation

7.5.1.1 Importing Medical Devices into the U.S.

7.5.1.2 Exporting Medical Devices from the U.S.

7.5.2 U.K. Regulation

7.5.3 E.U. Regulation

7.5.3.1 French Regulation

7.5.4 Japanese Regulation

7.5.5 Korean Regulation; 7.6 Increased Market Penetration; 7.7 Costs of Doing Business in Europe; 7.8 Drivers of European Diagnostics Testing; 7.9 European Reimbursement Practices; 7.10 Cost Containment in Europe
8. Technology Platform Innovations in POCT: 8.1 Sensor Systems for Diagnostic Applications; 8.2 Glucose Measurements; 8.3 Glucose Test Methods; 8.4 Cholesterol Testing; 8.5 The New Paradigm; 8.6 Consolidated Workstations and Modularity; 8.7 Automation and Robotics in the Clinical Laboratory; 8.8 Laboratory Information Systems (LIS)

8.8.1 NOVIUS Lab; 8.9 Biosensor Technology; 8.10 Nanogen Third Generaton POC Analyzer; 8.11 Quidel MChip
9. Data Management and Connectivity: 9.1 Wireless LANs; 9.2 Connectivity Platforms; 9.2.1 DataLink Data Management System

9.2.2 RALS-Plus

9.2.3 BD.id; 9.3 Advantages of POCT Connectivity

9.3.1 Cost Benefit of POCT and IT Connectivity
10. Corporate Profiles: 10.1 Abaxis, Inc.; 10.2 Abbott Diagnostics; 10.3 Accumetrics, Inc.; 10.4 Accurex Biomedical, Pvt., Ltd.; 10.5 Akers Biosciences; 10.6 Alfa Scientific Design, Inc.; 10.7 Ambri, Ltd.; 10.8 American Bio Medica Corp.; 10.9 Ani Biotech; 10.10 Apogent Technologies; 10.11 Ark Therapeutics; 10.12 ARKRAY; 10.13 Atlas Genetics; 10.14 Atonomics; 10.15 Avitar, Inc.; 10.16 Avox Systems; 10.17 Axis-Shield; 10.18 Beckman Coulter; 10.19 Binax Corporation; 10.20 Biomerica; 10.21 BioM�rieux Vitek, Inc.; 10.22 BioScan Screening Systems, Inc.; 10.23 Biosite Diagnostics; 10.24 BioStar; 10.25 British Biocell Holdings; 10.26 Caliper Life Sciences; 10.27 Calypte Biomedical; 10.28 Chembio Diagnostics; 10.29 Cholestech; 10.30 Chongqing Sungene Pharmaceutical Co., Ltd.; 10.31 CompuCyte Corporation; 10.32 Cortech Diagnostics Ltd. (now called Kent International Holdings); 10.33 Cozart Biosciences; 10.34 Cygnus Therapeutic Systems; 10.35 Cytogen; 10.36 Dade Behring; 10.37 Daiichi Sankyo Group; 10.38 Denka Seiken Co., Ltd.; 10.39 Diagnostic Chemicals, Ltd.; 10.40 Enterix, Inc.; 10.41 Focus Diagnostics, Inc.; 10.42 GDS Technology; 10.43 GenBio; 10.44 Genzyme Diagnostics; 10.45 Grant Life Sciences; 10.46 Gryphus Diagnostics; 10.47 Helena Laboratories; 10.48 Hema Diagnostic Systems; 10.49 Hemocue, Inc.; 10.50 Home Access Health Corp.; 10.51 Immunoscience, Inc.; 10.52 Instrumentation Laboratory; 10.53 International Medical Innovations; 10.54 Inverness Medical Innovations; 10.55 Johnson & Johnson; 10.56 Kyowa Medex Co., Ltd.; 10.57 LifeAssays; 10.58 LifePoint, Inc.; 10.59 LifeScan Corporation; 10.60 Lifestream Technologies; 10.61 LXN Corp. (Inverness Medical Technologies); 10.62 Matritech; 10.63 Medical Services International, Inc.; 10.64 MediSense; 10.65 Medisys; 10.66 Medix Biochemica; 10.67 MedMira Laboratories; 10.68 Meretek Corporation; 10.69 Meridian Bioscience; 10.70 MiniMed; 10.71 Mitsubishi Chemical USA, Inc.; 10.72 Mitsubishi Kagaku Iatron; 10.73 Nanogen; 10.74 New Horizons Diagnostics; 10.75 Nova Biomedical; 10.76 OraSure; 10.77 Orgenics; 10.78 Orion Diagnostica; 10.79 PanBio, Ltd.; 10.80 Phamatech, Inc.; 10.81 PharmaNetics, Inc.; 10.82 Polymedco; 10.83 Polymer Technology Systems; 10.84 Princeton BioMeditech Corporation; 10.85 Quest Diagnostics; 10.86 Quidel; 10.87 Radiometer; 10.88 Response Biomedical Corp.; 10.89 Roche Diagnostics; 10.90 Royal Philips Electronics; 10.91 Savyon Diagnostics; 10.92 Selfcare, Inc.; 10.93 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech); 10.94 Shionogi & Co., Ltd.; 10.95 Siemens Corporation; 10.96 SpectRx, Inc.; 10.97 Spectral Diagnostics; 10.98 StatSure Diagnostic Systems; 10.99 STC Technologies; 10.100 Strategic Diagnostics; 10.101 Sun Biomedical Laboratories; 10.102 Sybron International Corporation; 10.103 Thermo Biostar; 10.104 Thoratec/International Technidyne Corp.; 10.105 Transmedica; 10.106 Trinity Biotech; 10.107 V�samed, Inc.; 10.108 Venkateshwara Hatcheries Pvt., Ltd.; 10.109 Worldwide Medical Corporation
11. POCT Sector Trends and Forecasts: 11.1 Home Care Analysis as Part of Near-Patient Testing; 11.2 Non-Traditional Collection for POCT; 11.3 New Systems for Critical Care and Near-Patient Testing; 11.4 Utility of Near-Patient Testing in Critical Care Settings; 11.5 Physician�s Office Market; 11.6 Information Management Advances; 11.7 Test-Ordering Patterns and Demand for POCT; 11.8 Demand for Emergency Department Services; 11.9 Move Away From Central Laboratory; 11.10 Healthcare Cost Controls; 11.11 M&A in POCT; 11.12 Competition for Services; 11.13 Drivers of POCT; 11.14 Confluence of New Technology; 11.15 Difficulties of Design for POC Products; 11.16 European Hospital Structure; 11.17 The Biggest New Opportunities in Point of Care Testing
12. Corporate Directory
LIST OF FIGURES: Figure 3.1: Worldwide Distribution of IVD Testing, 2007; Figure 3.2: Global Point of Care Testing Share of Total In Vitro Diagnostic; Testing Market, 2007; Figure 4.1: Number of HbA1c Tests Performed Globally as POCT, 1991-2006; Figure 4.2: Total Spending on Healthcare in the U.S., 1960-2007; Figure 4.3: International Per Capita Healthcare Spending Per Country, 2006; Figure 6.1: Annual Rate of Emergency Room Visits By Primary Expected Source of; Payment: U.S., 2004
INDEX OF TABLES: Table 2.1: POC Testing; Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2005; Table 3.2: Number of Point of Care Tests in U.S., 2000-2012; Table 3.3: Global Clinical Laboratory Market Sales, 1998-2010; Table 3.4: The Overall In Vitro Diagnostic Testing Market Worldwide in 2007; Table 3.5: Worldwide Distribution of IVD Testing in 2007; Table 3.6: Top Twelve Country IVD Testing Markets, 2007; Table 3.7: Thirteen Largest Diagnostic Companies Worldwide, 2007; Table 3.8: Global Point of Care Revenues, 2005-2012; Table 3.9: Worldwide POCT Market Size by Geographic Location, 2005-2012; Table 3.10: Worldwide Distribution of POCT, 2007; Table 3.11: Worldwide POCT by Performance Location, 2007; Table 3.12: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments, 2007; Table 3.13: Largest POCT Diagnostic Companies Worldwide, 2007; Table 3.14: U.S. Clinical Laboratory Testing Market, 2003-2012; Table 3.15: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location of Analysis, 2007; Table 3.16: U.S. POCT Market, 2000-2012; Table 3.17: U.S. POCT by Performance Location, 2007; Table 3.18: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2007; Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments Market ($), 2000-2012; Table 3.20: European Clinical Laboratory Testing IVD Reagents and Instruments Market, 2000-2012; Table 3.21: European Clinical Laboratory Testing Diagnostics by Country Market stimates, 2007; Table 3.22: European Rapid Point of Care Testing by Country Market Estimates,2007; Table 3.23: Regional Comparison of Healthcare Spending for IVD for Eastern Europe; Table 3.24: European POCT Market, 2005-2012; Table 3.25: Top Twelve Country IVD and POC Testing Markets, 2007; Table 3.26: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012; Table 3.27: German POCT Diagnostics Products Market Sales, 2003-2012; Table 3.28: German Clinical Diagnostic Rapid Test Market Segments, 2007; Table 3.29: U.K. Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.30: U.K. POCT Diagnostics Products Market Sales, 2006-2012; Table 3.31: U.K. Clinical Diagnostic Rapid Test Market Segments, 2007; Table 3.32: Major U.K. IVD Manufacturers; Table 3.33: U.S. IVD Manufacturers Doing Business in the U.K.; Table 3.34: Other European Companies that Manufacture IVD Products in the U.K.; Table 3.35: French Clinical IVD Testing Diagnostics Products Market Sales, 2003-2012; Table 3.36: French POCT Diagnostics Products Market Sales, 2005-2012; Table 3.37: French Clinical Diagnostic Rapid Test Market Segments, 2007; Table 3.38: Italian Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.39: Italian POCT Diagnostics Products Market Sales, 2005-2012; Table 3.40: Italian Clinical Diagnostic Rapid Test Market Segments, 2007; Table 3.41: Spanish Clinical Laboratory Diagnostics Products Market Sales,; 2003-2012; Table 3.42: Spanish Clinical Diagnostic Rapid Test Market Segments, 2007; Table 3.43: Spanish POCT Diagnostics Products Market Sales, 2005-2012; Table 3.44: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012; Table 3.45: Swedish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.46: Swedish POCT Diagnostics Products Market Sales, 2005-2012; Table 3.47: Finnish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.48: Finnish POCT Diagnostics Products Market Sales, 2005-2012; Table 3.49: Norwegian Clinical Laboratory Diagnostics Products Market Sales,2003-2012; Table 3.50: Norwegian POCT Diagnostics Products Market Sales, 2005-2012; Table 3.51: Swiss Clinical Laboratory Diagnostics Products Market Sales,2003-2012; Table 3.52: Swiss POCT Diagnostics Products Market Sales, 2005-2012; Table 3.53: Dutch Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.54: Dutch POCT Diagnostics Products Market Sales, 2005-2012; Table 3.55: Belgium Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.56: Belgium POCT Diagnostics Products Market Sales, 2005-2012; Table 3.57: Portuguese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.58: Portuguese POCT Diagnostics Products Market Sales, 2005-2012; Table 3.59: Austrian Clinical Laboratory Diagnostics Products Market Sales,2003-2012; Table 3.60: Austrian POCT Diagnostics Products Market Sales, 2005-2012; Table 3.61: Greek Clinical Laboratory Diagnostics Products Market Sales,2003-2012; Table 3.62: Greek POCT Diagnostics Products Market Sales, 2005-2012; Table 3.63: Polish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012; Table 3.64: Polish POCT Diagnostics Products Market Sales, 2005-2012; Table 3.65: Czech Clinical Laboratory Diagnostics Products Market Sales, 2004-2012; Table 3.66: Czech POCT Diagnostics Products Market Sales, 2005-2012; Table 3.67: Turkish POCT Market, 2000-2012; Table 3.68: Japan POCT Market, 2000-2012; Table 3.69: Japanese Population and Aging Demographics Forecast, 2000-2050; Table 3.70: Indian IVD Market for Instruments and Reagents, 2004-2012; Table 3.71: Number of Automated Clinical Labs in India, 2004-2012; Table 3.72: Indian IVD Market, 2007; Table 3.73: Indian POCT Diagnostics Products Market Sales, 2000-2008; Table 3.74: Chinese IVD Market, 2006-2012; Table 3.75: Number of Automated Clinical Labs in China, 2004-2012; Table 3.76: Chinese IVD Market, 2007; Table 3.77: Chinese POCT Diagnostics Products Market Sales, 2000-2012; Table 3.78: The Rest of the World POCT Market, 2000-2012; Table 3.79: Canadian POCT Market, 2000-2012; Table 3.80: Brazilian POCT Market, 2000-2012; Table 3.81: Australian POCT Market, 2000-2012; Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers; Table 4.2: The Global Population of Persons with Diabetes, 1995 and 2025; Table 4.3: The Glucose Testing Market for POCT Worldwide, 2001-2012; Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012; Table 4.5: Manufacturer Market Share U.S. POCT Market, 2007; Table 4.6: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment; Table 4.7: The HbA1c Testing Market for POCT Worldwide, 2006-2012; Table 4.8: The Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012; Table 4.9: The Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012; Table 4.10: Location Market Share of Critical Care Blood Gas Testing; Table 4.11: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2007; Table 4.12: The Coagulation Testing Market for POCT Worldwide, 2006-2012; Table 4.13: The Hand-held Coagulation Testing Market for POCT Worldwide, 2006-2012; Table 4.14: The Coagulation Market for POCT in the U.S., 2001-2012; Table 4.15: The POC Prothrombin Market for POCT in the U.S., 2000-2007; Table 4.16: The Cardiac Marker Market for POCT in the U.S., 2001-2012; Table 4.17: The Cardiac Marker Market for POCT Worldwide, 2001-2012; Table 4.18: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2007; Table 4.19: The Cardiac Marker Market for POCT in Europe, 2001-2011; Table 4.20: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2012; Table 4.21: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2012; Table 4.22: Drug Testing Needs Tier 1 for Rapid Serum Point of Care Testing in the Emergency Department; Table 4.23: Stat Urine Testing Drug Recommendations; Table 4.24: Device Specifications for POCT Breath Alcohol Analysis; Table 4.25: Global Point of Care Urine Test Strip Testing Market, 2001-2007; Table 4.26: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012; Table 4.27: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011; Table 4.28: U.S. Point of Care Urine Test Strip Testing Market Share; Table 4.29: Medicare Fee Schedule for Urine Chemistry Testing; Table 4.30: Pregnancy Testing Market for POCT Worldwide, 2006-2012; Table 4.31: U.S. Point of Care Pregnancy Testing Market, 2001-2012; Table 4.32: International Point of Care Pregnancy Testing Markets, 2001-2007; Table 4.33: U.S. Market Share for Rapid Point of Care Pregnancy Tests; Table 4.34: Hemoglobin Testing Market for POCT Worldwide, 2006-2012; Table 4.35: Worldwide POCT Market for HIV, 2001-2012; Table 4.36: U.S. POCT Market for HIV, 2001-2012; Table 4.37: Countries with the Highest Prevalence of HIV/AIDS; Table 4.38: FDA-Approved Rapid HIV Antibody Screening Tests; Table 4.39: OraSure OraQuick Rapid HIV Test Revenues, 2005; Table 4.40: The Cholesterol Testing Market for POCT Worldwide, 2006-2012; Table 4.41: The Infectious Disease Testing Market for POCT Worldwide, 2006-2012; Table 4.42: Salmonella Testing Market, 2002-2007; Table 4.43: Worldwide Point of Care Influenza Testing Market, 2002-2007; Table 4.44: U.S. Point of Care Influenza Testing Market, 2002-2007; Table 4.45: International Point of Care Influenza Testing Markets, 2002-2007; Table 4.46: U.S. Market for Rapid Point of Care Influenza Tests, 2007; Table 4.47: Worldwide Point of Care Strep A Testing Market, 2002-2007; Table 4.48: U.S. Point of Care Strep A Testing Market, 2002-2007; Table 4.49: International Point of Care Strep A Testing Markets, 2002-2007; Table 4.50: U.S. Market for Rapid Point of Care for Group A Strep Tests; Table 4.51: Global Market for Chlamydia Diagnostic Testing, 2000-2009; Table 4.52: U.S. Market for Chlamydia Diagnostic Testing, 2000-2009; Table 4.54: Global Market for Gonorrhea Diagnostic Testing, 2000-2009; Table 4.55: Global Market for TB Diagnostic Testing, 2000-2008; Table 4.56: U.S. Anthrax Test Market; Table 5.1: Drug Test Sensitivity Cut-Off Levels Established as Standard by NIDA, WHO and SAMHSA for Drugs of Abuse; Table 5.2: Major Competitors in the Drugs of Abuse Testing Market Segment; Table 5.3: Major Competitors in the Drugs of Abuse Oral Testing Market Segment; Table 5.4: Major Competitors in the Drugs of Abuse Urine Testing Market Segment; Table 5.5: Major Competitors in the Drugs of Abuse Saliva Testing Market Segment; Table 5.6 Siemens Urinalysis Near-patient Devices; Table 5.7: ColoCARE Fecal Occult Blood Test; Table 5.8: Type of Hepatitis Test: Lateral Flow; Table 5.9: Flow-Through; Table 5.10: Agglutination; Table 5.11: Immunoblot; Table 5.12: AmniSure; Table 6.1: Access Points; Table 6.2: Desktop Adapters�One Computer; Table 6.3: Desktop Adapters�Four Computers; Table 6.4: PCMCIA Adapters; Table 6.5: POCT1-Compliant Connectivity Point of Care Instruments; Table 6.6: POCT Clinical Outcomes in Diabetic Ketoacidosis; Table 6.7: POCT Clinical Outcomes in Arterial Blood Gas Measurements; Table 6.8: POCT in Three Hospitals. Cost Analysis with Labor Included; Table 6.9: Cost Analysis for Glucose Testing: POCT vs. Central Lab; Table 6.10: Financial Comparison for Moderate and Waived CLIA Labs; Table 7.1 Key Changes in IVD Business Structure; Table 7.2 Business Trends in Point of Care Testing; Table 7.3 Key Players Bring Business Developments to Point of Care DiagnosticTesting; Table 8.1: Normal Glucose Values�Fasting State; Table 9.1: Applications for Wireless LAN Technology; Table 9.2: Customized Reports Must Support CAP and JCAHO Requirements; Table 9.3 RALS-Plus Point of Care Market Share; Table 9.4: Applications of RALS Connectivity with POCT Devices; Table 10.1: Abaxis Blood Analysis Diagnostic Tests; Table 10.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers; Table 10.3: Products Marketed by Abbott in the Diagnostic Market; Table 10.4: Quidel Product Sales Distribution and Sales, 2007; Table 11.1: Improvements in Achieving ED Operational Efficiency Using POCT; Table 11.2: Test Menu and TAT for ED; Table 11.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED; Table 11.4: Key Areas and Metrics That Hospitals Measure To Assess Efficiency of ED; Table 11.5: Estimates of Patient Costs by DRG